

References

S-274

Genetic Diseases and Acquired Anemia

1. InterQual® Level of Care Criteria 2021. Acute Care Adult. McKesson Health Solutions, LLC.
2. Zhu Y, Gao Q, Hu J, Liu X, Guan D, Zhang F. Allo-HSCT compared with immunosuppressive therapy for acquired aplastic anemia: A system review and meta-analysis. *BMC Immunol.* 2020;21(1):1-11.
3. Iguchi A, Cho Y, Yabe H, et al. Long-term outcome and chimerism in patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation: A retrospective nationwide survey. *Int J Hematol.* 2019;110(3):364-369.
4. Hashem H, Abu AR, Auletta JJ, et al. Successful second hematopoietic cell transplantation in severe congenital neutropenia. *Pediatr Transplant.* 2018;22(1):1.
5. Shadur B, Zaidman I, NaserEddin A, et al. Successful hematopoietic stem cell transplantation for osteopetrosis using reduced intensity conditioning. *Pediatr Blood Cancer.* 2018;65(6):1.
6. Yabe M, Morio T, Tabuchi K, et al. Long-term outcome in patients with Fanconi anemia who received hematopoietic stem cell transplantation: A retrospective nationwide analysis. *Int J Hematol.* 2021;113(1):134-144.
7. Myers K, Hebert K, Antin J, et al. Hematopoietic stem cell transplantation for ShwachmanDiamond syndrome. *Biol Blood Marrow Transplant.* 2020;26(8):1446-1451.
8. Cesaro S, Pillon M, Sauer M, et al. Long-term outcome after allogeneic hematopoietic stem cell transplantation for Shwachman-Diamond syndrome: A retrospective analysis and a review of the literature by the Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation (SAAWP-EBMT). *Bone Marrow Transplant.* 2020;55(9):1796-1809.
9. ElGohary G, El Fakih R, de Latour R, et al. Haploidentical hematopoietic stem cell transplantation in aplastic anemia: A systematic review and meta-analysis of clinical outcome on behalf of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation (SAAWP of EBMT). *Bone Marrow Transplant.* 2020;55(10):1906-1917.
10. Chiesa R, Wang J, Blok HJ, et al. Hematopoietic cell transplantation in chronic granulomatous disease: A study of 712 children and adults. *Blood.* 2020;136(10):1201-1211.

11. Burroughs LM, Petrovic A, Brazauskas R, et al. Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: A PIDTC report. *Blood*. 2020;135(23):2094-2105.

Autoimmune Diseases

1. Snowden JA, Sharrack B, Akil M, et al. Autologous haematopoietic stem cell transplantation (aHSCT) for severe resistant autoimmune and inflammatory diseases - A guide for the generalist. *Clin Med (Lond)*. 2018;18(4):329-334.
2. Sullivan K, Goldmuntz E, Keyes-Elstein L, et al. Myeloblative autologous stem-cell for severe scleroderma. *N Engl J Med*. 2018;378(1):35-47.
3. Patel L, Lim YJ, Randomized trials of autologous hematopoietic stem cell transplantation for diffuse cutaneous systemic sclerosis: Systematic review and meta-analysis with trial sequential analysis of overall mortality. *Blood*. 2018;132:612.
4. Hayes, Inc. Hayes Health Technology Assessment. Autologous hematopoietic stem cell transplantation for the treatment of systemic sclerosis. Lansdale, PA: Hayes, Inc.; 7/19/2019.
5. Sullivan KM, Majhail NS, Bredeson C, et al. Systemic sclerosis as an indication for autologous hematopoietic cell transplantation" position statement from the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2018;24:1961-1964.
6. Shouval R, Furie N, Raanani P, Nagler A, Gafter-Gvili A. Autologous hematopoietic stem cell transplantation for systemic sclerosis: A systematic review and meta-analysis. *Biol Blood Marrow Transplant*. 2018;24(5):937-944.
7. Burt RK, Balabanov R, Burman J, et al. Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: A randomized clinical trial. *JAMA*. 2019;321(2):165-174.
8. Ge F, Lin H, Li A, Chang T. Efficacy and safety of autologous hematopoietic stem-cell transplantation in multiple sclerosis: A systematic review and meta-analysis. *Neurol Sci*, 2019;40(3):479-487.
9. Burt RK, Han X, Gozdzik P, et al. Five year follow-up after autologous peripheral blood hematopoietic stem cell transplantation for refractory, chronic, corticosteroid-dependent systemic lupus erythematosus: Effect of conditioning regimen on outcome. *Bone Marrow Transplant*. 2018;53(6):692-700.
10. M F Silva J, Ladomenou F, Carpenter B, et al. Allogeneic hematopoietic stem cell transplantation for severe, refractory juvenile idiopathic arthritis. *Blood Adv*. 2018;2(7):777-786.
11. Walicka M, Milczarczyk A, Snarski E, et al. Lack of persistent remission following initial recovery in patients with type 1 diabetes treated with

- autologous peripheral blood stem cell transplantation. *Diabetes Res Clin Pract.* 2018;143:357-363.
12. Brierley CK, Castilla-Llorente C, Labopin M, et al. Autologous haematopoietic stem cell transplantation for Crohn's disease: A retrospective survey of long-term outcomes from the European Society for Blood and Marrow Transplantation. *J Crohns Colitis.* 2018;29;12(9):1097-1103.
13. Rae-Grant A, Day GS, Marrie RA, et al. Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurol.* 2018;90(17):789-800.
14. Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. 2018;90(17):777-788.
15. Cohen JA, Baldassari LE, Atkins HL et al. Autologous hematopoietic cell transplantation for treatment-refractory relapsing multiple sclerosis: Position statement from the American Society for Blood and Marrow Transplantation. *Blood Marrow Transplant.* 2019;25(5).
16. Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: Management of Crohn's Disease in Adults. *Am J Gastroenterol.* 2018;113(4):481-517.
17. Kvistad SAS, Lehmann AK, Trovik LH, et al. Safety and efficacy of autologous hematopoietic stem cell transplantation for multiple sclerosis in Norway. *Mult Scler.* 2020;26(14):1889-1897.
18. Henes J, Oliveira MC, Labopin M, et al. Autologous stem cell transplantation for progressive systemic sclerosis: A prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party. *Haematol.* 2020.
19. van Bijnen S, de Vries-Bouwstra J, van den Ende CH, et al. Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: Results of a long-term follow-up multicentre study. *Ann Rheum Dis.* 2020;79(8):1084-1089.
20. Burt RK, Balabanov R, Tavee J, et al. Hematopoietic stem cell transplantation for chronic inflammatory demyelinating polyradiculoneuropathy. *J Neurol.* 2020;267(11):3378-3391.
21. Sun SY, Gao Y, Liu GJ, et al. Efficacy and safety of stem cell therapy for T1DM: An updated systematic review and meta-analysis. *J Diabetes Res.* 2020;5740923.

- 22.Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. 2020;96(3):114-122.
- 23.Boffa G, Massacesi L, Inglese M, et al. Long-term clinical outcomes of hematopoietic stem cell transplantation in multiple sclerosis. 2021;10.1212/WNL.0000000000011461.
- 24.Burt RK, Han X, Quigley K, Helenowski IB, Balabanov R. Real-world application of autologous hematopoietic stem cell transplantation in 507 patients with multiple sclerosis. *J Neurol*. 2022;269(5):2513-2526.
- 25.Kanate AS, Majhail NS, Savani BN, et al. Indications for hematopoietic cell transplantation and immune effector cell therapy: Guidelines from the American Society for Transplantation and Cellular Therapy. *Biol Blood Marrow Transplant*. 2020;26(7):1247-1256.
- 26.Ramalingam S, Shah A. stem cell therapy as a treatment for autoimmune disease-updates in lupus, scleroderma, and multiple sclerosis. *Current allergy and asthma reports*. 2021;21(3):22.
- 27.Levin D, Osman MS, Durand C, et al. Hematopoietic cell transplantation for systemic sclerosis-A review. *Cells*. 2022;11(23).